Atossa Therapeutics’ (ATOS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a research report report published on Thursday, Benzinga reports. They currently have a $6.00 price target on the stock.

Several other equities analysts have also recently issued reports on the company. Ascendiant Capital Markets lifted their price objective on Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a research note on Wednesday, September 11th. StockNews.com upgraded Atossa Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, October 25th.

Atossa Therapeutics Price Performance

NASDAQ ATOS opened at $1.42 on Thursday. The company has a market cap of $178.58 million, a P/E ratio of -6.76 and a beta of 1.20. The stock has a 50-day moving average of $1.43 and a two-hundred day moving average of $1.38. Atossa Therapeutics has a 1-year low of $0.62 and a 1-year high of $2.31.

Atossa Therapeutics (NASDAQ:ATOS) last released its earnings results on Monday, August 12th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, analysts anticipate that Atossa Therapeutics will post -0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Atossa Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new stake in Atossa Therapeutics during the second quarter worth approximately $29,000. Cetera Advisors LLC purchased a new stake in Atossa Therapeutics during the first quarter worth approximately $72,000. SG Americas Securities LLC lifted its stake in Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after purchasing an additional 30,037 shares during the last quarter. Virtu Financial LLC purchased a new stake in Atossa Therapeutics during the first quarter worth approximately $151,000. Finally, Rhumbline Advisers purchased a new stake in Atossa Therapeutics during the second quarter worth approximately $161,000. Hedge funds and other institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.